Concepedia

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

Jordan Amdahl, Jose Diaz, Arati Sharma, Jinhee Park, David Chandiwana, Thomas E. Delea

PLoS ONE · 2017 · 32 citations · 15 references

Open access

Abstract

Pazopanib is likely to be a cost-effective treatment option compared with sunitinib as first-line treatment of mRCC in the United Kingdom.

References

15

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

Urology, Genitourinary Cancer, Kidney Research +13

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, David Cella et al. · New England Journal of Medicine · 2013 · 1.9K citations · Full text

Net Health Benefits

Aaron A. Stinnett, John Mullahy · Medical Decision Making · 1998 · 1.1K citations

Probabilistic Sensitivity Analysis Using Monte Carlo Simulation

Peter M. Doubilet, Colin B. Begg, Milton C. Weinstein et al. · Medical Decision Making · 1985 · 844 citations

Bayesian Decision Theory, Engineering, Decision Analysis +19

SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA

Robert J. Motzer, Paul Russo · The Journal of Urology · 2000 · 605 citations